Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Sylvie Négrier, David Pérol, Rastislav Bahleda, Antoine Hollebecque, Etienne Chatelut, Helen Boyle, Philippe Cassier, Séverine Metzger, Ellen Blanc, Jean-Charles Soria, Bernard Escudier

ABSTRACT

BACKGROUND: Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been registered for clinical use in advanced renal cell carcinoma. The VEGFR TKI, pazopanib, with a rather manageable toxicity profile, was preferred to sunitinib by mRCC patients. We investigate the combination of pazopanib and bevacizumab to determine the maximum tolerated dose (MTD) in mRCC and other advanced solid tumors. METHODS: In this bicentric phase I trial with a 3 + 3 + 3 dose-escalation design, patients received oral pazopanib once daily plus intravenous infusion of bevacizumab every 2 weeks from D15, at one of the four dose levels (DL) planned according to the occurrence of dose limiting toxicities (DLT). 400 and 600 mg pazopanib were respectively combined with 7.5 mg/kg bevacizumab in DL1 and DL2, and 600 and 800 mg pazopanib with 10 mg/kg bevacizumab in DL3 and DL4. Tumor response was evaluated every 8 weeks. Blood samples were assayed to investigate pazopanib pharmacokinetics. RESULTS: Twenty five patients including seven mRCC were enrolled. Nine patients received the DL1, ten received the DL2. No DLT were observed at DL1, five DLT at DL2, and 3 DLT in the six additional patients who received the DL1. A grade 3 microangiopathic hemolytic anemia syndrome was observed in four (16%) patients. Five (22%) patients achieved a partial response. The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion. CONCLUSIONS: The combination of pazopanib and bevacizumab induces angiogenic toxicity in patients without any pre-existing renal or vascular damage. Even if a marginal efficacy was reported with five (22%) patients in partial response in different tumor types, the toxicity profile compromises the development of this combination. TRIAL REGISTRATION: The study was retrospectively registered on ClinicalTrials.gov (number NCT01202032 ) on 2010, Sept 14th. More... »

PAGES

547

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7

DOI

http://dx.doi.org/10.1186/s12885-017-3527-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091206574

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28810837


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Monitoring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "University Lyon, Universit\u00e9 Claude Bernard Lyon 1, Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "N\u00e9grier", 
        "givenName": "Sylvie", 
        "id": "sg:person.0723756046.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Clinical Research and Innovation Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "P\u00e9rol", 
        "givenName": "David", 
        "id": "sg:person.01221677717.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221677717.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "DITEP -D\u00e9partement d\u2019Innovation Th\u00e9rapeutiques et Essais Pr\u00e9coces, Institut  Gustave Roussy, 94805, Villejuif Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bahleda", 
        "givenName": "Rastislav", 
        "id": "sg:person.012307334207.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012307334207.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "DITEP -D\u00e9partement d\u2019Innovation Th\u00e9rapeutiques et Essais Pr\u00e9coces, Institut  Gustave Roussy, 94805, Villejuif Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hollebecque", 
        "givenName": "Antoine", 
        "id": "sg:person.0602246235.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602246235.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Paul Sabatier University", 
          "id": "https://www.grid.ac/institutes/grid.15781.3a", 
          "name": [
            "Institut Claudius Regaud, Inserm UMR1037 CRCT, Universit\u00e9 Paul-Sabatier, 20/24 rue du Pont Saint-Pierre, 31052, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chatelut", 
        "givenName": "Etienne", 
        "id": "sg:person.01333606250.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333606250.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boyle", 
        "givenName": "Helen", 
        "id": "sg:person.0616261742.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616261742.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cassier", 
        "givenName": "Philippe", 
        "id": "sg:person.01312356242.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312356242.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Metzger", 
        "givenName": "S\u00e9verine", 
        "id": "sg:person.011242133047.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011242133047.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blanc", 
        "givenName": "Ellen", 
        "id": "sg:person.01356177754.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356177754.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Paris-Sud", 
          "id": "https://www.grid.ac/institutes/grid.5842.b", 
          "name": [
            "University of Paris Sud, Orsay, Institut Gustave Roussy, 94805, Villejuif Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soria", 
        "givenName": "Jean-Charles", 
        "id": "sg:person.01225022325.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225022325.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Department of Medical Oncology, Institut Gustave Roussy, 114, rue Edouard-Vaillant, 94805, Villejuif Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "Bernard", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2004.11.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000451221"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.10.8332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000481419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.06.121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001303596"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1309748", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006159778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.21.6994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006983294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa061884", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008302687"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2535", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009131859"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-013-9976-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470509", 
          "https://doi.org/10.1007/s10637-013-9976-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-013-9976-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470509", 
          "https://doi.org/10.1007/s10637-013-9976-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-013-9976-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470509", 
          "https://doi.org/10.1007/s10637-013-9976-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-013-9976-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470509", 
          "https://doi.org/10.1007/s10637-013-9976-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61904-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010511397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00325-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011519120"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-013-2373-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011745965", 
          "https://doi.org/10.1007/s00280-013-2373-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2455-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012606735", 
          "https://doi.org/10.1007/s00280-014-2455-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa032691", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014051315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.60.9727", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016822150"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-0717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018539077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdm454", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018847020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020803009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(07)70037-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021597703"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00240-003-0346-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023624302", 
          "https://doi.org/10.1007/s00240-003-0346-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-2740", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025063112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.11.5154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027241718"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-0708", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029146743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1303989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030656737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30107-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031150467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa072113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033842397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0707330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036840499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa066838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037798278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/0284186x.2013.782103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039366876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)60651-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040046880"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2013.06.042", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040912245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.9847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041483211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2479-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041617704", 
          "https://doi.org/10.1007/s00280-014-2479-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70124-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046924268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3181c7307e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047443465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-1275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047556241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00290-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048871630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.0108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049557004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.50.8267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053397983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0708857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053513212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.29187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072293145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra1601333", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074211544"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been registered for clinical use in advanced renal cell carcinoma. The VEGFR TKI, pazopanib, with a rather manageable toxicity profile, was preferred to sunitinib by mRCC patients. We investigate the combination of pazopanib and bevacizumab to determine the maximum tolerated dose (MTD) in mRCC and other advanced solid tumors.\nMETHODS: In this bicentric phase I trial with a 3\u00a0+\u00a03\u00a0+\u00a03 dose-escalation design, patients received oral pazopanib once daily plus intravenous infusion of bevacizumab every 2 weeks from D15, at one of the four dose levels (DL) planned according to the occurrence of dose limiting toxicities (DLT). 400 and 600\u00a0mg pazopanib were respectively combined with 7.5\u00a0mg/kg bevacizumab in DL1 and DL2, and 600 and 800\u00a0mg pazopanib with 10\u00a0mg/kg bevacizumab in DL3 and DL4. Tumor response was evaluated every 8 weeks. Blood samples were assayed to investigate pazopanib pharmacokinetics.\nRESULTS: Twenty five patients including seven mRCC were enrolled. Nine patients received the DL1, ten received the DL2. No DLT were observed at DL1, five DLT at DL2, and 3 DLT in the six additional patients who received the DL1. A grade 3 microangiopathic hemolytic anemia syndrome was observed in four (16%) patients. Five (22%) patients achieved a partial response. The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) \u03bcg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) \u03bcg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.\nCONCLUSIONS: The combination of pazopanib and bevacizumab induces angiogenic toxicity in patients without any pre-existing renal or vascular damage. Even if a marginal efficacy was reported with five (22%) patients in partial response in different tumor types, the toxicity profile compromises the development of this combination.\nTRIAL REGISTRATION: The study was retrospectively registered on ClinicalTrials.gov (number NCT01202032 ) on 2010, Sept 14th.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-017-3527-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors", 
    "pagination": "547", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "dc58ef9d3d7658c236388b94c962245d927321db9b75adec9773af9d70ae4f9d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28810837"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-017-3527-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091206574"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-017-3527-7", 
      "https://app.dimensions.ai/details/publication/pub.1091206574"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113667_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-017-3527-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7'


 

This table displays all metadata directly associated to this object as RDF triples.

358 TRIPLES      21 PREDICATES      91 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-017-3527-7 schema:about N08abc413a3cb43d199a994529ea02da4
2 N0dcb838bd3864de2b93842b93f8f01a2
3 N29549532b65342249486adaf268a2c86
4 N2cbe12c2974c44f3b9f4973ed3cf0a76
5 N5eff8aa5c58c4000b6225660fb483e14
6 N6b774abda61e4c5b81e8ea2da2809835
7 N7eabd0d360a449b0ad9c779e589e6ad5
8 N86d6b0886e4747cfb4b8b6bb1196070b
9 N8e8bb7f031e9459baf90907bf8d8c697
10 Na527ec14b87a4bcf91bff55fbc1abd12
11 Nb076793878fd4d6f874821ce2ce50382
12 Nc146c6acb83641a19b33a1ec97d4701d
13 Nc5559ae4494f40b2b6d408680fa6067d
14 Ndd73df3c8118427fba9782ca675eab09
15 Nf919eee4aa864d7a9c316820bd099b22
16 Nffcbb612332146efb722c2261ce5f285
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N5a631821ff114207a7c19897155997d6
20 schema:citation sg:pub.10.1007/s00240-003-0346-x
21 sg:pub.10.1007/s00280-013-2373-9
22 sg:pub.10.1007/s00280-014-2455-3
23 sg:pub.10.1007/s00280-014-2479-8
24 sg:pub.10.1007/s10637-013-9976-1
25 https://doi.org/10.1016/j.ejca.2008.10.026
26 https://doi.org/10.1016/j.ejca.2013.06.042
27 https://doi.org/10.1016/s0140-6736(07)61904-7
28 https://doi.org/10.1016/s0140-6736(11)61613-9
29 https://doi.org/10.1016/s0140-6736(12)60651-5
30 https://doi.org/10.1016/s1470-2045(07)70037-2
31 https://doi.org/10.1016/s1470-2045(11)70124-3
32 https://doi.org/10.1016/s1470-2045(15)00290-9
33 https://doi.org/10.1016/s1470-2045(15)00325-3
34 https://doi.org/10.1016/s1470-2045(16)30107-3
35 https://doi.org/10.1056/nejmoa021491
36 https://doi.org/10.1056/nejmoa032691
37 https://doi.org/10.1056/nejmoa060655
38 https://doi.org/10.1056/nejmoa061884
39 https://doi.org/10.1056/nejmoa065044
40 https://doi.org/10.1056/nejmoa066838
41 https://doi.org/10.1056/nejmoa0707330
42 https://doi.org/10.1056/nejmoa0708857
43 https://doi.org/10.1056/nejmoa072113
44 https://doi.org/10.1056/nejmoa1303989
45 https://doi.org/10.1056/nejmoa1309748
46 https://doi.org/10.1056/nejmra1601333
47 https://doi.org/10.1093/annonc/mdm454
48 https://doi.org/10.1097/jto.0b013e3181c7307e
49 https://doi.org/10.1158/1078-0432.ccr-08-2740
50 https://doi.org/10.1158/1078-0432.ccr-09-0717
51 https://doi.org/10.1158/1078-0432.ccr-11-1275
52 https://doi.org/10.1158/1078-0432.ccr-12-2535
53 https://doi.org/10.1158/1078-0432.ccr-13-0708
54 https://doi.org/10.1200/jco.2004.06.121
55 https://doi.org/10.1200/jco.2004.11.022
56 https://doi.org/10.1200/jco.2007.10.8332
57 https://doi.org/10.1200/jco.2007.11.5154
58 https://doi.org/10.1200/jco.2008.16.9847
59 https://doi.org/10.1200/jco.2008.19.0108
60 https://doi.org/10.1200/jco.2008.21.6994
61 https://doi.org/10.1200/jco.2009.23.9764
62 https://doi.org/10.1200/jco.2013.50.8267
63 https://doi.org/10.1200/jco.2015.60.9727
64 https://doi.org/10.3109/0284186x.2013.782103
65 https://doi.org/10.4161/cbt.29187
66 schema:datePublished 2017-12
67 schema:datePublishedReg 2017-12-01
68 schema:description BACKGROUND: Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been registered for clinical use in advanced renal cell carcinoma. The VEGFR TKI, pazopanib, with a rather manageable toxicity profile, was preferred to sunitinib by mRCC patients. We investigate the combination of pazopanib and bevacizumab to determine the maximum tolerated dose (MTD) in mRCC and other advanced solid tumors. METHODS: In this bicentric phase I trial with a 3 + 3 + 3 dose-escalation design, patients received oral pazopanib once daily plus intravenous infusion of bevacizumab every 2 weeks from D15, at one of the four dose levels (DL) planned according to the occurrence of dose limiting toxicities (DLT). 400 and 600 mg pazopanib were respectively combined with 7.5 mg/kg bevacizumab in DL1 and DL2, and 600 and 800 mg pazopanib with 10 mg/kg bevacizumab in DL3 and DL4. Tumor response was evaluated every 8 weeks. Blood samples were assayed to investigate pazopanib pharmacokinetics. RESULTS: Twenty five patients including seven mRCC were enrolled. Nine patients received the DL1, ten received the DL2. No DLT were observed at DL1, five DLT at DL2, and 3 DLT in the six additional patients who received the DL1. A grade 3 microangiopathic hemolytic anemia syndrome was observed in four (16%) patients. Five (22%) patients achieved a partial response. The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion. CONCLUSIONS: The combination of pazopanib and bevacizumab induces angiogenic toxicity in patients without any pre-existing renal or vascular damage. Even if a marginal efficacy was reported with five (22%) patients in partial response in different tumor types, the toxicity profile compromises the development of this combination. TRIAL REGISTRATION: The study was retrospectively registered on ClinicalTrials.gov (number NCT01202032 ) on 2010, Sept 14th.
69 schema:genre research_article
70 schema:inLanguage en
71 schema:isAccessibleForFree true
72 schema:isPartOf Na67bc88f17a64f588ad8f3d77c76a41a
73 Ndb80b00ecdca45d7845b8414ff552588
74 sg:journal.1024632
75 schema:name Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
76 schema:pagination 547
77 schema:productId N1ac703ae52e04a3a82fa54436ccd2d9f
78 N755846c59dc34363b8aabb547558c1a1
79 N9d0f9f68703e4cca86a43c9544a84cd2
80 Nbad0b2c746db419a82b19c7f7fcf9f81
81 Ne3ab69faa2174d94b3bc43b59b526a02
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091206574
83 https://doi.org/10.1186/s12885-017-3527-7
84 schema:sdDatePublished 2019-04-11T10:35
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher Na88f3bb875c24599ac37f082b8f99bbc
87 schema:url https://link.springer.com/10.1186%2Fs12885-017-3527-7
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N08abc413a3cb43d199a994529ea02da4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Combined Modality Therapy
93 rdf:type schema:DefinedTerm
94 N0dcb838bd3864de2b93842b93f8f01a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Pyrimidines
96 rdf:type schema:DefinedTerm
97 N1ac703ae52e04a3a82fa54436ccd2d9f schema:name readcube_id
98 schema:value dc58ef9d3d7658c236388b94c962245d927321db9b75adec9773af9d70ae4f9d
99 rdf:type schema:PropertyValue
100 N29549532b65342249486adaf268a2c86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Humans
102 rdf:type schema:DefinedTerm
103 N2cbe12c2974c44f3b9f4973ed3cf0a76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Antineoplastic Combined Chemotherapy Protocols
105 rdf:type schema:DefinedTerm
106 N341c37ef35c14832ab6db30b9cfcfbe4 rdf:first sg:person.01225022325.73
107 rdf:rest N4ec924810ceb4d41bd359c36c399b54c
108 N4ec924810ceb4d41bd359c36c399b54c rdf:first sg:person.01304252172.82
109 rdf:rest rdf:nil
110 N5a631821ff114207a7c19897155997d6 rdf:first sg:person.0723756046.31
111 rdf:rest Na5d886a95d40496abb4a7c2528aca72e
112 N5eff8aa5c58c4000b6225660fb483e14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Bevacizumab
114 rdf:type schema:DefinedTerm
115 N6b774abda61e4c5b81e8ea2da2809835 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Sulfonamides
117 rdf:type schema:DefinedTerm
118 N6f9927f561314258b1c98eb25dc0fce9 rdf:first sg:person.01333606250.74
119 rdf:rest N839e7dbfd1f34a079c26689e9dc21a9b
120 N755846c59dc34363b8aabb547558c1a1 schema:name dimensions_id
121 schema:value pub.1091206574
122 rdf:type schema:PropertyValue
123 N7eabd0d360a449b0ad9c779e589e6ad5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Adult
125 rdf:type schema:DefinedTerm
126 N81f5d07eb04f488695871d6a992c5992 rdf:first sg:person.01356177754.57
127 rdf:rest N341c37ef35c14832ab6db30b9cfcfbe4
128 N839e7dbfd1f34a079c26689e9dc21a9b rdf:first sg:person.0616261742.66
129 rdf:rest Nb360cd6246de4082992b66a4c4fac7f9
130 N86d6b0886e4747cfb4b8b6bb1196070b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Middle Aged
132 rdf:type schema:DefinedTerm
133 N8e8bb7f031e9459baf90907bf8d8c697 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Maximum Tolerated Dose
135 rdf:type schema:DefinedTerm
136 N9a970b09caf24a27bbac9bb44fffb167 schema:name University Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
137 rdf:type schema:Organization
138 N9d0f9f68703e4cca86a43c9544a84cd2 schema:name doi
139 schema:value 10.1186/s12885-017-3527-7
140 rdf:type schema:PropertyValue
141 Na527ec14b87a4bcf91bff55fbc1abd12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 Na5d886a95d40496abb4a7c2528aca72e rdf:first sg:person.01221677717.00
145 rdf:rest Ndb66c113e1f64bd1bc66c26437dbd558
146 Na67bc88f17a64f588ad8f3d77c76a41a schema:volumeNumber 17
147 rdf:type schema:PublicationVolume
148 Na88f3bb875c24599ac37f082b8f99bbc schema:name Springer Nature - SN SciGraph project
149 rdf:type schema:Organization
150 Nb076793878fd4d6f874821ce2ce50382 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Male
152 rdf:type schema:DefinedTerm
153 Nb360cd6246de4082992b66a4c4fac7f9 rdf:first sg:person.01312356242.78
154 rdf:rest Nb904a24ce71b4fc5a0309d6ab8e9f1e2
155 Nb904a24ce71b4fc5a0309d6ab8e9f1e2 rdf:first sg:person.011242133047.80
156 rdf:rest N81f5d07eb04f488695871d6a992c5992
157 Nbad0b2c746db419a82b19c7f7fcf9f81 schema:name nlm_unique_id
158 schema:value 100967800
159 rdf:type schema:PropertyValue
160 Nc146c6acb83641a19b33a1ec97d4701d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Treatment Outcome
162 rdf:type schema:DefinedTerm
163 Nc5559ae4494f40b2b6d408680fa6067d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Female
165 rdf:type schema:DefinedTerm
166 Ndb66c113e1f64bd1bc66c26437dbd558 rdf:first sg:person.012307334207.98
167 rdf:rest Nf0d206b1fc7f434e8aafacc37b68bf02
168 Ndb80b00ecdca45d7845b8414ff552588 schema:issueNumber 1
169 rdf:type schema:PublicationIssue
170 Ndd73df3c8118427fba9782ca675eab09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Kidney Neoplasms
172 rdf:type schema:DefinedTerm
173 Ne3ab69faa2174d94b3bc43b59b526a02 schema:name pubmed_id
174 schema:value 28810837
175 rdf:type schema:PropertyValue
176 Nf0d206b1fc7f434e8aafacc37b68bf02 rdf:first sg:person.0602246235.37
177 rdf:rest N6f9927f561314258b1c98eb25dc0fce9
178 Nf919eee4aa864d7a9c316820bd099b22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Drug Monitoring
180 rdf:type schema:DefinedTerm
181 Nffcbb612332146efb722c2261ce5f285 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Carcinoma, Renal Cell
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
188 schema:name Clinical Sciences
189 rdf:type schema:DefinedTerm
190 sg:journal.1024632 schema:issn 1471-2407
191 schema:name BMC Cancer
192 rdf:type schema:Periodical
193 sg:person.011242133047.80 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
194 schema:familyName Metzger
195 schema:givenName Séverine
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011242133047.80
197 rdf:type schema:Person
198 sg:person.01221677717.00 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
199 schema:familyName Pérol
200 schema:givenName David
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221677717.00
202 rdf:type schema:Person
203 sg:person.01225022325.73 schema:affiliation https://www.grid.ac/institutes/grid.5842.b
204 schema:familyName Soria
205 schema:givenName Jean-Charles
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225022325.73
207 rdf:type schema:Person
208 sg:person.012307334207.98 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
209 schema:familyName Bahleda
210 schema:givenName Rastislav
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012307334207.98
212 rdf:type schema:Person
213 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
214 schema:familyName Escudier
215 schema:givenName Bernard
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
217 rdf:type schema:Person
218 sg:person.01312356242.78 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
219 schema:familyName Cassier
220 schema:givenName Philippe
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312356242.78
222 rdf:type schema:Person
223 sg:person.01333606250.74 schema:affiliation https://www.grid.ac/institutes/grid.15781.3a
224 schema:familyName Chatelut
225 schema:givenName Etienne
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333606250.74
227 rdf:type schema:Person
228 sg:person.01356177754.57 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
229 schema:familyName Blanc
230 schema:givenName Ellen
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356177754.57
232 rdf:type schema:Person
233 sg:person.0602246235.37 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
234 schema:familyName Hollebecque
235 schema:givenName Antoine
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602246235.37
237 rdf:type schema:Person
238 sg:person.0616261742.66 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
239 schema:familyName Boyle
240 schema:givenName Helen
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616261742.66
242 rdf:type schema:Person
243 sg:person.0723756046.31 schema:affiliation N9a970b09caf24a27bbac9bb44fffb167
244 schema:familyName Négrier
245 schema:givenName Sylvie
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31
247 rdf:type schema:Person
248 sg:pub.10.1007/s00240-003-0346-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023624302
249 https://doi.org/10.1007/s00240-003-0346-x
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s00280-013-2373-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011745965
252 https://doi.org/10.1007/s00280-013-2373-9
253 rdf:type schema:CreativeWork
254 sg:pub.10.1007/s00280-014-2455-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012606735
255 https://doi.org/10.1007/s00280-014-2455-3
256 rdf:type schema:CreativeWork
257 sg:pub.10.1007/s00280-014-2479-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041617704
258 https://doi.org/10.1007/s00280-014-2479-8
259 rdf:type schema:CreativeWork
260 sg:pub.10.1007/s10637-013-9976-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010470509
261 https://doi.org/10.1007/s10637-013-9976-1
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/j.ejca.2013.06.042 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040912245
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/s0140-6736(07)61904-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010511397
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1016/s0140-6736(12)60651-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040046880
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1016/s1470-2045(07)70037-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021597703
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1016/s1470-2045(11)70124-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046924268
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1016/s1470-2045(15)00290-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048871630
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1016/s1470-2045(15)00325-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011519120
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1016/s1470-2045(16)30107-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031150467
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1056/nejmoa021491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020803009
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1056/nejmoa032691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014051315
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1056/nejmoa061884 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008302687
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1056/nejmoa066838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037798278
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1056/nejmoa0707330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036840499
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1056/nejmoa0708857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053513212
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1056/nejmoa072113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033842397
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1056/nejmoa1303989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030656737
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1056/nejmoa1309748 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006159778
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1056/nejmra1601333 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074211544
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1093/annonc/mdm454 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018847020
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1097/jto.0b013e3181c7307e schema:sameAs https://app.dimensions.ai/details/publication/pub.1047443465
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1158/1078-0432.ccr-08-2740 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025063112
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1158/1078-0432.ccr-09-0717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018539077
314 rdf:type schema:CreativeWork
315 https://doi.org/10.1158/1078-0432.ccr-11-1275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047556241
316 rdf:type schema:CreativeWork
317 https://doi.org/10.1158/1078-0432.ccr-12-2535 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009131859
318 rdf:type schema:CreativeWork
319 https://doi.org/10.1158/1078-0432.ccr-13-0708 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029146743
320 rdf:type schema:CreativeWork
321 https://doi.org/10.1200/jco.2004.06.121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001303596
322 rdf:type schema:CreativeWork
323 https://doi.org/10.1200/jco.2004.11.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000451221
324 rdf:type schema:CreativeWork
325 https://doi.org/10.1200/jco.2007.10.8332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000481419
326 rdf:type schema:CreativeWork
327 https://doi.org/10.1200/jco.2007.11.5154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027241718
328 rdf:type schema:CreativeWork
329 https://doi.org/10.1200/jco.2008.16.9847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041483211
330 rdf:type schema:CreativeWork
331 https://doi.org/10.1200/jco.2008.19.0108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049557004
332 rdf:type schema:CreativeWork
333 https://doi.org/10.1200/jco.2008.21.6994 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006983294
334 rdf:type schema:CreativeWork
335 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
336 rdf:type schema:CreativeWork
337 https://doi.org/10.1200/jco.2013.50.8267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053397983
338 rdf:type schema:CreativeWork
339 https://doi.org/10.1200/jco.2015.60.9727 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016822150
340 rdf:type schema:CreativeWork
341 https://doi.org/10.3109/0284186x.2013.782103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039366876
342 rdf:type schema:CreativeWork
343 https://doi.org/10.4161/cbt.29187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072293145
344 rdf:type schema:CreativeWork
345 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
346 schema:name DITEP -Département d’Innovation Thérapeutiques et Essais Précoces, Institut Gustave Roussy, 94805, Villejuif Cedex, France
347 Department of Medical Oncology, Institut Gustave Roussy, 114, rue Edouard-Vaillant, 94805, Villejuif Cedex, France
348 rdf:type schema:Organization
349 https://www.grid.ac/institutes/grid.15781.3a schema:alternateName Paul Sabatier University
350 schema:name Institut Claudius Regaud, Inserm UMR1037 CRCT, Université Paul-Sabatier, 20/24 rue du Pont Saint-Pierre, 31052, Toulouse, France
351 rdf:type schema:Organization
352 https://www.grid.ac/institutes/grid.418116.b schema:alternateName Centre Léon Bérard
353 schema:name Clinical Research and Innovation Department, Centre Léon Bérard, F-69373, Lyon, Cedex 08, France
354 Medical Oncology Department, Centre Léon Bérard, F-69373, Lyon, Cedex 08, France
355 rdf:type schema:Organization
356 https://www.grid.ac/institutes/grid.5842.b schema:alternateName University of Paris-Sud
357 schema:name University of Paris Sud, Orsay, Institut Gustave Roussy, 94805, Villejuif Cedex, France
358 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...